Modifiable dementia risk factors: the Lancet Commission frame
The most useful public-health frame for lifelong cognitive health is not a single brain game. It is the life-course model of modifiable dementia risk synthesized by the Lancet Commission on dementia prevention, intervention, and care. This page explains that model, highlights high-leverage factors (including hearing loss and the ACHIEVE trial), and draws a hard line around what “modifiable” does — and does not — promise.
neurogym.club is educational only. We do not diagnose, treat, or sell interventions. Individual risk and medical decisions belong with licensed clinicians.
The Lancet Commission life-course model
The Lancet Commission reports (including the 2024 update, Livingston et al.) organize dementia risk across early life, midlife, and later life. Earlier reports already emphasized factors such as less education, hearing loss, hypertension, physical inactivity, diabetes, smoking, depression, social isolation, and others. The 2024 update incorporates newer evidence and refines the set and relative importance of factors — including attention to hearing and, in recent commission work, vision impairment among emerging considerations.
Primary source (confirmed 2026-07-21):
- Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404(10452):572–628. PubMed
Read the commission as population science: it estimates how much of dementia cases at a population level might be attributable to modifiable factors if those factors were reduced. That is not the same as a personal risk calculator with guaranteed outcomes.
Largest modifiable levers (plain language)
Without substituting for the full commission table, the high-signal themes for readers are:
| Domain | Why it appears in the model | Practical angle |
|---|---|---|
| Hearing loss (midlife) | Large population attributable fraction in commission analyses; sensory deprivation and social withdrawal pathways are discussed | Get hearing assessed; treat when indicated |
| Hypertension & vascular disease | Vascular brain injury contributes to cognitive decline and mixed dementias | Blood pressure care is brain care |
| Diabetes & metabolic health | Linked to vascular and neurodegenerative risk pathways | Glycemic and weight management with clinicians |
| Physical inactivity | Overlaps the exercise–cognition trial literature | See Exercise and cognition |
| Smoking | Vascular and inflammatory harm | Cessation remains high value |
| Social isolation | Observational links to dementia risk; intervention evidence thinner | Stay connected; treat isolation as health-relevant |
| Education / cognitive engagement (life course) | Early and ongoing cognitive reserve concepts | Learning is not the same as app drills |
| Sleep & air quality / other factors | Appear in broader risk discussions with varying evidence strength | Avoid overclaiming single factors |
Exact ranking of population attributable fractions should be taken from the commission paper itself, not from secondary blogs (including this one). We summarize themes; we do not invent percentages.
Hearing loss and the ACHIEVE trial (2023)
Marketing and headlines sometimes say “hearing aids prevent dementia.” The careful version is narrower and more interesting.
ACHIEVE (Aging and Cognitive Health Evaluation in Elders) was a multicenter randomized trial of a hearing intervention versus a health-education control in older adults with hearing loss in the USA. Results reported in The Lancet (Lin et al., 2023) showed:
- No overall effect on the primary cognitive outcome at three years in the full randomized sample.
- A pre-specified subgroup analysis found a substantial protective effect on cognition in a higher-risk subgroup recruited from the ARIC cohort (older, lower baseline cognition, more vascular/metabolic risk factors) compared with healthier volunteers who answered advertisements.
Sources (confirmed 2026-07-21):
- Lin FR et al. Hearing intervention versus health education control to reduce cognitive decline… (ACHIEVE). The Lancet. 2023. Trial discussion also appears in the Lancet Commission 2024 materials summarizing ACHIEVE’s overall null primary outcome and ARIC-subgroup signal.
How to read that honestly:
- Hearing care is still justified for communication, safety, and quality of life — independent of dementia endpoints.
- Population models can rank untreated hearing loss highly as a modifiable risk factor even when a single trial’s primary analysis is null.
- Subgroup findings generate hypotheses and highlight who might benefit most; they are not a blank check that “hearing aids stop Alzheimer’s” for everyone.
- The commission still treats hearing as a major modifiable factor based on the totality of evidence, not ACHIEVE alone.
What “modifiable” does and does not mean
Does mean:
- At a population level, reducing risk factors is associated with fewer dementia cases.
- Individuals can often improve hearing access, blood pressure, activity, smoking status, and metabolic health with clinical support.
- Prevention is multi-decade and multi-factor, not a weekend cleanse.
Does not mean:
- A personal guarantee that you will avoid dementia if you optimize every factor.
- That genetics, age, and unmodifiable biology stop mattering.
- That any commercial product citing “Lancet” has been endorsed by the commission (the commission does not endorse consumer apps).
- That population attributable fraction equals your personal probability.
How this fits with exercise, sleep, and apps
- Exercise and cognition covers the trial/meta-analytic case for aerobic and resistance training.
- Sleep and memory covers consolidation and duration recommendations (CDC/AASM).
- Do brain-training apps work? covers why far-transfer claims from games are weaker than the multi-domain risk model.
If you only have attention for three actions this year: treat hearing and vision problems you can treat, move your body, and manage blood pressure and metabolic risk with a clinician. That list is boring on purpose. Boring is where the evidence lives.
Bottom line
The Lancet Commission’s life-course model is the adult way to think about cognitive health: many levers, decades of runway, no single silver bullet. ACHIEVE shows why careful reading of trials matters — overall nulls and high-risk subgroup signals can coexist. Stay suspicious of any product that converts commission science into a subscription pitch.
Sources checked as of 2026-07-21. Educational only; not medical advice.